HealthTree Radio for AML: Eytan Stein, MD, Memorial Sloan Kettering

Allogeneic stem cell transplantation is the only curative option for patients battling acute myeloid leukemia. However, a significant number of patients will relapse after transplant. Innovative resea...

5 Loka 20221h 2min

The IDH mutation can be found in approximately 20% of adult AML cases. Isocitrate dehydrogenase isoform 1 and 2 or IDH1 and IDH2 mutations are typically found in older AML patients and have an interme...

24 Elo 202258min

The TP53 mutation in AML is considered to be a high risk mutation and occurs in approximately 5-10% of patients. This genetic mutation has been difficult to treat, often being chemoresistant with a po...

14 Heinä 20221h 1min

The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients. It occurs in up to 37% of adult patients with AML. FLT3 mutations have been harder to treat with poor outcom...

29 Kesä 20221h

Immunotherapy continues to be an expanding and evolving area of research for AML with many drugs in development. One drug currently being studied is IMGN632, an antibody drug conjugate, that targets C...

9 Kesä 202258min

Immunotherapy is one of the most promising areas of cancer research. Drugs like checkpoint inhibitors, monoclonal and bispecific anitbodies, antibody drug conjugates and CAR-T cell therapy are all ext...

26 Touko 20221h 1min

About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several d...

7 Helmi 202256min